Log in

NASDAQ:MISTMilestone Pharmaceuticals Stock Price, Forecast & News

$3.16
-0.03 (-0.94 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.11
Now: $3.16
$3.26
50-Day Range
$1.95
MA: $2.92
$3.97
52-Week Range
$1.69
Now: $3.16
$27.95
Volume358,528 shs
Average Volume2.38 million shs
Market Capitalization$77.77 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina. The company was founded in 2003 and is headquartered in Montréal, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.10 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MIST
CUSIPN/A
CIKN/A
Phone514-336-0444

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.05 per share

Profitability

Net Income$-55,230,000.00

Miscellaneous

Employees20
Market Cap$77.77 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive MIST News and Ratings via Email

Sign-up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter.

Milestone Pharmaceuticals (NASDAQ:MIST) Frequently Asked Questions

How has Milestone Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Milestone Pharmaceuticals' stock was trading at $19.99 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MIST stock has decreased by 84.2% and is now trading at $3.16. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Milestone Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Milestone Pharmaceuticals in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Milestone Pharmaceuticals.

When is Milestone Pharmaceuticals' next earnings date?

Milestone Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Milestone Pharmaceuticals.

How were Milestone Pharmaceuticals' earnings last quarter?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) issued its earnings results on Thursday, May, 14th. The company reported ($0.67) EPS for the quarter, topping analysts' consensus estimates of ($0.74) by $0.07. View Milestone Pharmaceuticals' earnings history.

What price target have analysts set for MIST?

6 analysts have issued 12-month target prices for Milestone Pharmaceuticals' shares. Their forecasts range from $3.00 to $32.00. On average, they expect Milestone Pharmaceuticals' share price to reach $21.42 in the next twelve months. This suggests a possible upside of 577.7% from the stock's current price. View analysts' price targets for Milestone Pharmaceuticals.

Has Milestone Pharmaceuticals been receiving favorable news coverage?

Media stories about MIST stock have trended very negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Milestone Pharmaceuticals earned a media sentiment score of -3.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutMilestone Pharmaceuticals.

Are investors shorting Milestone Pharmaceuticals?

Milestone Pharmaceuticals saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 398,100 shares, a decrease of 8.8% from the April 30th total of 436,500 shares. Based on an average daily trading volume, of 1,520,000 shares, the days-to-cover ratio is currently 0.3 days. Currently, 3.2% of the company's stock are short sold. View Milestone Pharmaceuticals' Current Options Chain.

Who are some of Milestone Pharmaceuticals' key competitors?

What other stocks do shareholders of Milestone Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Milestone Pharmaceuticals investors own include Allena Pharmaceuticals (ALNA), Opko Health (OPK), AbbVie (ABBV), Walt Disney (DIS), Gilead Sciences (GILD), SCYNEXIS (SCYX), Amplify Energy (AMPY), Amplify Energy (AMPY), Energy Transfer LP Unit (ET) and Menlo Therapeutics (MNLO).

Who are Milestone Pharmaceuticals' key executives?

Milestone Pharmaceuticals' management team includes the following people:
  • Mr. Joseph G. Oliveto, CEO, Pres & Director (Age 51)
  • Dr. Philippe Douville, Founder & Chief Scientific Officer (Age 57)
  • Mr. Timothy L. Maness, VP of Fin. (Age 59)
  • Dr. Francis Plat, Chief Medical Officer (Age 61)
  • Mr. Lorenz Muller, Chief Commercial Officer (Age 55)

When did Milestone Pharmaceuticals IPO?

(MIST) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

What is Milestone Pharmaceuticals' stock symbol?

Milestone Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIST."

Who are Milestone Pharmaceuticals' major shareholders?

Milestone Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Tekla Capital Management LLC (0.87%), Ghost Tree Capital LLC (0.85%), Sphera Funds Management LTD. (0.28%) and UBS Group AG (0.05%). Company insiders that own Milestone Pharmaceuticals stock include Holdings A/S Novo, Rtw Investments, Lp and Stonepine Capital, LP. View institutional ownership trends for Milestone Pharmaceuticals.

Which major investors are selling Milestone Pharmaceuticals stock?

MIST stock was sold by a variety of institutional investors in the last quarter, including Tekla Capital Management LLC, and Ghost Tree Capital LLC. View insider buying and selling activity for Milestone Pharmaceuticals.

Which major investors are buying Milestone Pharmaceuticals stock?

MIST stock was purchased by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., and UBS Group AG. Company insiders that have bought Milestone Pharmaceuticals stock in the last two years include Holdings A/S Novo, Rtw Investments, Lp, and Stonepine Capital, LP. View insider buying and selling activity for Milestone Pharmaceuticals.

How do I buy shares of Milestone Pharmaceuticals?

Shares of MIST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Milestone Pharmaceuticals' stock price today?

One share of MIST stock can currently be purchased for approximately $3.16.

How big of a company is Milestone Pharmaceuticals?

Milestone Pharmaceuticals has a market capitalization of $77.77 million. The company earns $-55,230,000.00 in net income (profit) each year or ($3.50) on an earnings per share basis. Milestone Pharmaceuticals employs 20 workers across the globe.

What is Milestone Pharmaceuticals' official website?

The official website for Milestone Pharmaceuticals is www.milestonepharma.com.

How can I contact Milestone Pharmaceuticals?

Milestone Pharmaceuticals' mailing address is 1111 DR. FREDERIK-PHILIPS BLVD SUITE 420, MONTREAL A8, H4M 2X6. The company can be reached via phone at 514-336-0444 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.